Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
Checked against the public recordLast updated Dec 21, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: RAD001; Drug: erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: * Age over 18 years * Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment including either cisplatin or carboplatin * Only 1-2 previous chemotherapy regimens for advanced disease * More than 2 weeks from previous surgery, radiation or chemotherapy * Ability to perform normal daily functions Exclusion criteria: * Chronic steroid treatment * Prior treatment with EGFR inhibitors * Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions or other severe medical conditions * Other cancers within the past 2 years * Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria may apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Novartis Investigative SiteAtlanta, Georgia
- Novartis Investigative SiteChicago, Illinois
- Novartis Investigative SiteBoston, Massachusetts
- Novartis Investigative SiteRochester, Minnesota
- Novartis Investigative SiteNashville, Tennessee
- Novartis Investigative SiteHouston, Texas
- Novartis Investigative SiteMadison, Wisconsin
- Novartis Investigative SiteRichmond, British Columbia
- Novartis Investigative SiteToronto, Ontario
- Novartis Investigative SiteMontreal, Quebec
- Novartis Investigative SiteHerlev
- Novartis Investigative SiteSaint-Herblain Cédex
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 21, 2020. Always confirm current availability with the study team.